How local biotech Aegros plans to shake up CSLâs home turf Save Share Itâs been a 30-plus year journey for small plasma fractionation biotech Aegros, but the COVID-19 pandemic and the resulting global plasma shortage have provided the catalysts it needed to gain commercial traction for its product. The company, which raised $5 million in a round led by Barclay Pearce late last year, specialises in splitting plasma into proteins such as immunoglobulin and albumin, which are used to create therapies to treat a range of conditions including immune deficiencies. Dr Hari Nair and John Manusuâs Aegros may be a start-up, but the companyâs technology is based on more than 30 years of work.Â